Pub Date : 2024-01-01Epub Date: 2024-03-08DOI: 10.1159/000538085
Zhanar Kurmangali, Bibigul Abdykalykova, Aimen Kurmangali, Danat Zhantagulov, Milan Terzic
Introduction: The purpose of the research was to explore the relationship between pathology and pregnancy outcomes with serum 25-hydroxycholecalciferol levels and vitamin D supplementation.
Methods: A literature search was performed for systematic literature reviews published between January 2018 and February 2023. Forty-two publications were selected for further analysis.
Results: This study demonstrates that elevated maternal serum 25(OH)D levels are associated with a decreased risk of preterm labour and various pregnancy-related health issues, highlighting the protective benefits of adequate vitamin D during pregnancy.
Conclusion: Vitamin D supplementation during pregnancy at a dose of 2,000 IU or higher is preventive for pre-eclampsia, insulin resistance, and the development of bronchial asthma in early childhood. Vitamin D screening is indicated for all pregnant women. Dosages of vitamin D preparations should be determined individually, considering laboratory tests and risk factors.
维生素 D 缺乏会增加不良妊娠结局的风险。维生素 D 缺乏症在全球的高发率要求对科学出版物进行分析,以便为孕妇维生素 D 缺乏症的预防、管理和治疗提出建议。研究的目的是探讨病理学和妊娠结局与血清 25- 羟基胆钙化醇水平和维生素 D 补充剂之间的关系。研究人员对2018年1月至2023年2月期间发表的带有荟萃分析的系统性文献综述进行了文献检索。选取了 42 篇文献进行进一步分析。24项荟萃分析评估了血清25-羟基胆钙化醇水平与妊娠过程和结果之间的关系。18 项荟萃分析侧重于维生素 D 制剂对产科和儿科病理发展的预防作用。研究发现,缺乏维生素 D 会增加自然流产(OR=1.6 (1.11; 2.3))、早产(OR=1.33 (1.15; 1.54)),尤其是多胎妊娠(OR=2.59 (1.35; 4.95))、先兆子痫(OR=1.33 (1.15; 1.54))的概率。95)、先兆子痫(OR=1.58(1.39-1.79))、妊娠贫血(OR=1.61(1.41;1.83))、产后抑郁(OR=3.67(1.72;7.85))、幼儿期自闭症谱系障碍(OR=1.54(1.12;2.1))。高维生素 D 水平可降低妊娠糖尿病(RR=0.87 (0.79; 0.97))和低出生体重(RR=0.65 (0.48; 0.86))的风险。孕期 25- 羟维生素 D 的目标水平是血清浓度超过 30 毫克/毫升。孕期补充 2000 IU 或更高剂量的维生素 D 可预防先兆子痫、胰岛素抵抗和幼儿期支气管哮喘的发生。维生素 D 筛查适用于所有孕妇。维生素 D 制剂的剂量应根据实验室检测结果和风险因素单独确定。
{"title":"The Influence of Vitamin D on Pregnancy and Outcomes: Current Knowledge and Future Perspectives.","authors":"Zhanar Kurmangali, Bibigul Abdykalykova, Aimen Kurmangali, Danat Zhantagulov, Milan Terzic","doi":"10.1159/000538085","DOIUrl":"10.1159/000538085","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of the research was to explore the relationship between pathology and pregnancy outcomes with serum 25-hydroxycholecalciferol levels and vitamin D supplementation.</p><p><strong>Methods: </strong>A literature search was performed for systematic literature reviews published between January 2018 and February 2023. Forty-two publications were selected for further analysis.</p><p><strong>Results: </strong>This study demonstrates that elevated maternal serum 25(OH)D levels are associated with a decreased risk of preterm labour and various pregnancy-related health issues, highlighting the protective benefits of adequate vitamin D during pregnancy.</p><p><strong>Conclusion: </strong>Vitamin D supplementation during pregnancy at a dose of 2,000 IU or higher is preventive for pre-eclampsia, insulin resistance, and the development of bronchial asthma in early childhood. Vitamin D screening is indicated for all pregnant women. Dosages of vitamin D preparations should be determined individually, considering laboratory tests and risk factors.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"261-266"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-03-25DOI: 10.1159/000538519
Musa Temel, Merve Durmuş, Şeyma Eroğlu Durmaz, Deniz Güvenir, Erdem Gürkaş
Objectives: Posterior reversible encephalopathy syndrome (PRES) is a clinic radiological disorder characterized by headache, epileptic seizure, encephalopathy, visual impairment, and focal neurological deficits. Gestational hypertension, which is a significant risk factor for PRES, may cause significant morbidity and mortality among pregnant women.
Design: Twenty-four patients with PRES caused by eclampsia who were admitted to our hospital in the last 5 years were included in this study.
Participants/materials, setting, methods: Blood pressure at admission, the number of regions with vasogenic edema in the brain, and recurrent seizures were noted. Patients were divided into three groups: mild, moderate, and severe.
Results: Using Kruskal-Wallis and Pearson χ2 tests, there was no statistical significance between the groups in terms of cranial involvement (p = 0.471). However, binary logistic regression analysis showed that seizure recurrence increased in correlation with blood pressure (p = 0.04).
Limitations: PRES is a rare syndrome associated with several etiologies. In our study, only patients with PRES due to eclampsia were included. Therefore, the number of included patients was limited (24 participants).
Conclusion: PRES may occur in eclamptic patients with mild, moderate, or severe blood pressure values. Evaluation by magnetic resonance imaging is needed to confirm the diagnosis. Early and rapid treatment is essential for reducing morbidity and mortality among pregnant women.
{"title":"Posterior Reversible Encephalopathy Syndrome in Eclamptic Patients: The Relationship between Blood Pressure, Cranial Involvement, and Seizure Recurrence.","authors":"Musa Temel, Merve Durmuş, Şeyma Eroğlu Durmaz, Deniz Güvenir, Erdem Gürkaş","doi":"10.1159/000538519","DOIUrl":"10.1159/000538519","url":null,"abstract":"<p><strong>Objectives: </strong>Posterior reversible encephalopathy syndrome (PRES) is a clinic radiological disorder characterized by headache, epileptic seizure, encephalopathy, visual impairment, and focal neurological deficits. Gestational hypertension, which is a significant risk factor for PRES, may cause significant morbidity and mortality among pregnant women.</p><p><strong>Design: </strong>Twenty-four patients with PRES caused by eclampsia who were admitted to our hospital in the last 5 years were included in this study.</p><p><strong>Participants/materials, setting, methods: </strong>Blood pressure at admission, the number of regions with vasogenic edema in the brain, and recurrent seizures were noted. Patients were divided into three groups: mild, moderate, and severe.</p><p><strong>Results: </strong>Using Kruskal-Wallis and Pearson χ2 tests, there was no statistical significance between the groups in terms of cranial involvement (p = 0.471). However, binary logistic regression analysis showed that seizure recurrence increased in correlation with blood pressure (p = 0.04).</p><p><strong>Limitations: </strong>PRES is a rare syndrome associated with several etiologies. In our study, only patients with PRES due to eclampsia were included. Therefore, the number of included patients was limited (24 participants).</p><p><strong>Conclusion: </strong>PRES may occur in eclamptic patients with mild, moderate, or severe blood pressure values. Evaluation by magnetic resonance imaging is needed to confirm the diagnosis. Early and rapid treatment is essential for reducing morbidity and mortality among pregnant women.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"330-334"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-12-27DOI: 10.1159/000535982
Giusi Santangelo, Antonio Simone Lagana, Andrea Giannini, Filippo Murina, Camilla Di Dio, Gianfilippo Ruggiero, Violante Di Donato, Giorgia Perniola, Margherita Fischetti, Assunta Casorelli, Francesco Clemente, Marianna Minnetti, Francesco Lombardo, Pierluigi Benedetti Panici, Ludovico Muzii, Giorgio Bogani
Background: The role of hormonal replacement therapy in menopause is under debate. The premature closure of the Women's Health Initiative (WHI) study in 2002 is still a source of concern among treating physicians.
Objectives: The interest in alternatives to conventional hormone therapy has significantly increased. The adoption of personalized steroid hormone galenic preparations, formulated by compounding pharmacies, has recently spread.
Methods: In June 2023, an extensive literature search was conducted by different authors to identify relevant studies in various databases (MEDLINE, Embase, PubMed, and Cochrane). The studies that met the inclusion and exclusion criteria were further analyzed, and relevant data were extracted and analyzed for each paper. Any discrepancies between the investigators were resolved through a consensus approach.
Outcomes: The primary outcomes observed included the clinical utility of CBHT. This study reviewed the current evidence on the utility of compounded bioidentical hormones, concluding that improving knowledge and awareness of bioidentical hormones is necessary to consider their use in clinical practice.
Conclusion and outlook: These formulations might provide effective options to best tailor therapies to each patient.
{"title":"Spotlight on Compounded Bioidentical Hormones.","authors":"Giusi Santangelo, Antonio Simone Lagana, Andrea Giannini, Filippo Murina, Camilla Di Dio, Gianfilippo Ruggiero, Violante Di Donato, Giorgia Perniola, Margherita Fischetti, Assunta Casorelli, Francesco Clemente, Marianna Minnetti, Francesco Lombardo, Pierluigi Benedetti Panici, Ludovico Muzii, Giorgio Bogani","doi":"10.1159/000535982","DOIUrl":"10.1159/000535982","url":null,"abstract":"<p><strong>Background: </strong>The role of hormonal replacement therapy in menopause is under debate. The premature closure of the Women's Health Initiative (WHI) study in 2002 is still a source of concern among treating physicians.</p><p><strong>Objectives: </strong>The interest in alternatives to conventional hormone therapy has significantly increased. The adoption of personalized steroid hormone galenic preparations, formulated by compounding pharmacies, has recently spread.</p><p><strong>Methods: </strong>In June 2023, an extensive literature search was conducted by different authors to identify relevant studies in various databases (MEDLINE, Embase, PubMed, and Cochrane). The studies that met the inclusion and exclusion criteria were further analyzed, and relevant data were extracted and analyzed for each paper. Any discrepancies between the investigators were resolved through a consensus approach.</p><p><strong>Outcomes: </strong>The primary outcomes observed included the clinical utility of CBHT. This study reviewed the current evidence on the utility of compounded bioidentical hormones, concluding that improving knowledge and awareness of bioidentical hormones is necessary to consider their use in clinical practice.</p><p><strong>Conclusion and outlook: </strong>These formulations might provide effective options to best tailor therapies to each patient.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"31-40"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-06-12DOI: 10.1159/000531499
Lesley M McMahon, Caroline M Joyce, Lyndsey Cuthill, Hugh Mitchell, Imran Jabbar, Fred Sweep
Objectives: The objective of this study was to collect information on human chorionic gonadotrophin (hCG) laboratory testing and reporting in women with gestational trophoblastic disease (GTD), to assess the associated challenges, and to offer perspectives on hCG testing harmonisation.
Design: Information was collected from laboratories by electronic survey (SurveyMonkey) using a questionnaire designed by members of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD) hCG working party.
Participants: The questionnaire was distributed by the EOTTD board to member laboratories and their associated scientists who work within the GTD field.
Setting: The questionnaire was distributed and accessed via an online platform.
Methods: The questionnaire consisted of 5 main sections. These included methods used for hCG testing, quality procedures, reporting of results, laboratory operational aspects, and non-GTD testing capability. In addition to reporting these survey results, examples of case scenarios which illustrate the difficulties faced by laboratories providing hCG measurement for GTD patient management were described. The benefits and challenges of using centralised versus non-centralised hCG testing were discussed alongside the utilisation of regression curves for management of GTD patients.
Results: Information from the survey was collated and presented for each section and showed huge variability in responses across laboratories even for those using the same hCG testing platforms. An educational example was presented, highlighting the consequence of using inappropriate hCG assays on clinical patient management (Educational Example A), along with an example of biotin interference (Educational Example B) and an example of high-dose hook effect (Educational Example C), demonstrating the importance of knowing the limitations of hCG tests. The merits of centralised versus non-centralised hCG testing and use of hCG regression curves to aid patient management were discussed.
Limitations: To ensure the survey was completed by laboratories providing hCG testing for GTD management, the questionnaire was distributed by the EOTTD board. It was assumed the EOTTD board held the correct laboratory contact, and that the questionnaire was completed by a scientist with in-depth knowledge of laboratory procedures.
Conclusions: The hCG survey highlighted a lack of harmonisation of hCG testing across laboratories. Healthcare professionals involved in the management of women with GTD should be aware of this limitation. Further work is needed to ensure an appropriate, quality-assured laboratory service is available for hCG monitoring in women with GTD.
{"title":"Measurement of Human Chorionic Gonadotrophin in Women with Gestational Trophoblastic Disease.","authors":"Lesley M McMahon, Caroline M Joyce, Lyndsey Cuthill, Hugh Mitchell, Imran Jabbar, Fred Sweep","doi":"10.1159/000531499","DOIUrl":"10.1159/000531499","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to collect information on human chorionic gonadotrophin (hCG) laboratory testing and reporting in women with gestational trophoblastic disease (GTD), to assess the associated challenges, and to offer perspectives on hCG testing harmonisation.</p><p><strong>Design: </strong>Information was collected from laboratories by electronic survey (SurveyMonkey) using a questionnaire designed by members of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD) hCG working party.</p><p><strong>Participants: </strong>The questionnaire was distributed by the EOTTD board to member laboratories and their associated scientists who work within the GTD field.</p><p><strong>Setting: </strong>The questionnaire was distributed and accessed via an online platform.</p><p><strong>Methods: </strong>The questionnaire consisted of 5 main sections. These included methods used for hCG testing, quality procedures, reporting of results, laboratory operational aspects, and non-GTD testing capability. In addition to reporting these survey results, examples of case scenarios which illustrate the difficulties faced by laboratories providing hCG measurement for GTD patient management were described. The benefits and challenges of using centralised versus non-centralised hCG testing were discussed alongside the utilisation of regression curves for management of GTD patients.</p><p><strong>Results: </strong>Information from the survey was collated and presented for each section and showed huge variability in responses across laboratories even for those using the same hCG testing platforms. An educational example was presented, highlighting the consequence of using inappropriate hCG assays on clinical patient management (Educational Example A), along with an example of biotin interference (Educational Example B) and an example of high-dose hook effect (Educational Example C), demonstrating the importance of knowing the limitations of hCG tests. The merits of centralised versus non-centralised hCG testing and use of hCG regression curves to aid patient management were discussed.</p><p><strong>Limitations: </strong>To ensure the survey was completed by laboratories providing hCG testing for GTD management, the questionnaire was distributed by the EOTTD board. It was assumed the EOTTD board held the correct laboratory contact, and that the questionnaire was completed by a scientist with in-depth knowledge of laboratory procedures.</p><p><strong>Conclusions: </strong>The hCG survey highlighted a lack of harmonisation of hCG testing across laboratories. Healthcare professionals involved in the management of women with GTD should be aware of this limitation. Further work is needed to ensure an appropriate, quality-assured laboratory service is available for hCG monitoring in women with GTD.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"178-197"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9624713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-05-08DOI: 10.1159/000539265
Sara Korošec, Gaetano Riemma, Vesna Šalamun, Anita Franko Rutar, Antonio Simone Laganà, Vito Chiantera, Pasquale De Franciscis, Helena Ban Frangež
<p><strong>Objectives: </strong>The objective of the study was to evaluate the prevalence and impact of impaired thyroid-stimulating hormone (TSH) levels on the reproductive outcomes of in vitro fertilization patients diagnosed with endometriosis and compared to controls without endometriosis.</p><p><strong>Design: </strong>This is a retrospective cohort study on prospectively collected data.</p><p><strong>Setting: </strong>The study was conducted at tertiary care university hospital.</p><p><strong>Participants: </strong>Participants were infertile women with histopathological diagnosis of endometriosis.</p><p><strong>Methods: </strong>For 12 months (January 2018 to January 2019), women were deemed suitable and subsequently divided according to serum TSH levels above or below 2.5 mIU/L and compared to patients without endometriosis. Needed sample size was at least 41 patients for each cohort of women. Co-primary outcomes were the live birth rate (LBR), clinical pregnancy rate (CPR), and pregnancy loss rate (PLR).</p><p><strong>Results: </strong>Overall, 226 women (45 with endometriosis and 181 controls without endometriosis) were included. Diagnoses of Hashimoto thyroiditis were significantly more frequent in women with rather than without endometriosis (14/45 [31.1%] vs. 27/181 [14.9%]; p = 0.012). Similarly, in women with endometriosis, Hashimoto diagnosis rates were higher with TSH ≥2.5 mIU/L compared to TSH <2.5 mIU/L (9/15 [60%] vs.5/30 [16.6%]; p = 0.001) so were the Hashimoto diagnosis rates in control group (women without endometriosis) with TSH ≥2.5 mIU/L compared to TSH <2.5 mIU/L (17/48 [35.4%] vs. 10/133 [7.5%], respectively; p = 0.001). Effect size analysis confirmed an increased risk of Hashimoto thyroiditis in women with endometriosis and TSH ≥2.5 mIU/L compared to women with endometriosis and TSH <2.5 mIU/L (risk ratio [RR] 3.60 [95% CI 1.46-8.86]) and in women with endometriosis and TSH ≥2.5 mIU/L compared to non-endometriotic euthyroid patients (RR 7.98 [95% CI 3.86-16.48]). Dysmenorrhea risk was higher in endometriotic euthyroid women compared to euthyroid patients with no endometriosis (RR 1.87 [95% CI 1.21-2.87]). The risk was still increased in euthyroid women with endometriosis relative to dysthyroid women with no endometriosis (RR 1.97 [95% CI 1.11-3.50]). There were no significant differences between the four groups for CPR, LBR, PLR and retrieved oocytes, immature oocytes, degenerated and unfertilized oocytes, cultured blastocysts, embryos and transferred embryos.</p><p><strong>Limitations: </strong>Limitations of the study were retrospective design, limited sample size, and use of different ovarian stimulation protocol.</p><p><strong>Conclusions: </strong>Thyroid autoimmunity seems more common in women with endometriosis and TSH over 2.5 mIU/L. However, there was no significant impact on in vitro fertilization and reproductive outcomes related to the coexistence of endometriosis, Hashimoto disease, and higher T
目的评估被诊断患有子宫内膜异位症的体外受精患者与未患有子宫内膜异位症的对照组相比,促甲状腺激素(TSH)水平受损的发生率及其对生殖结果的影响:设计:对前瞻性收集的数据进行回顾性队列研究:地点:大学附属三级医院组织病理学诊断为子宫内膜异位症的不孕妇女.方法:在12个月内(2018年1月至2019年1月),认为妇女适合,随后根据血清促甲状腺激素水平高于或低于2.5 mIU/L进行划分,并与无子宫内膜异位症的患者进行比较。每组妇女至少需要41名患者。共同主要结果为活产率(LBR)、临床妊娠率(CPR)和妊娠损失率(PLR)。在患有子宫内膜异位症的妇女中,桥本甲状腺炎的诊断率明显高于未患子宫内膜异位症的妇女(14/45 (31.1%) vs 27/181 (14.9%);P=0.012)。同样,在患有子宫内膜异位症的妇女中,TSH ≥2.5 mIU/L 的桥本氏病诊断率高于 TSH <2.5 mIU/L 的诊断率(9/15(60%) vs 5/30(16.6%);P=0.001),对照组(无子宫内膜异位症的妇女)TSH ≥2.5 mIU/L 与 TSH <2.5 mIU/L 相比的桥本氏诊断率也是如此(分别为 17/48 (35.4%) vs 10/133 (7.5%); p=0.001)。效应大小分析证实,与患有子宫内膜异位症且TSH <2.5 mIU/L的妇女相比,患有子宫内膜异位症且TSH ≥2.5 mIU/L的妇女患桥本氏甲状腺炎的风险增加(风险比 (RR) 3.60 (95% CI 1.46 to 8.86));与非子宫内膜异位症甲状腺功能正常的患者相比,患有子宫内膜异位症且TSH ≥2.5 mIU/L的妇女患桥本氏甲状腺炎的风险增加(RR 7.98 (95% CI 3.86 to 16.48))。与无子宫内膜异位症的甲状腺功能亢进患者相比,子宫内膜异位症甲状腺功能亢进妇女的痛经风险更高(RR 1.87 (95% CI 1.21 to 2.87))。有子宫内膜异位症的甲状腺功能亢进妇女与无子宫内膜异位症的甲状腺功能减退妇女相比,风险仍然增加(RR 1.97 (95% CI 1.11 to 3.50))。四组之间在CPR、LBR、PLR以及取回的卵母细胞、未成熟卵母细胞、退化和未受精卵母细胞、培养的囊胚、胚胎和移植的胚胎方面没有明显差异:局限性:回顾性设计,样本量有限,使用了不同的卵巢刺激方案:结论:甲状腺自身免疫似乎在患有子宫内膜异位症且促甲状腺激素超过2.5 mIU/L的妇女中更为常见。然而,子宫内膜异位症、桥本氏病和较高的促甲状腺激素水平同时存在,对体外受精和生殖结果并无明显影响。由于研究的局限性,还需要更多的证据来验证上述发现。
{"title":"Coexistence of Endometriosis and Thyroid Autoimmunity in Infertile Women: Impact on in vitro Fertilization and Reproductive Outcomes.","authors":"Sara Korošec, Gaetano Riemma, Vesna Šalamun, Anita Franko Rutar, Antonio Simone Laganà, Vito Chiantera, Pasquale De Franciscis, Helena Ban Frangež","doi":"10.1159/000539265","DOIUrl":"10.1159/000539265","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of the study was to evaluate the prevalence and impact of impaired thyroid-stimulating hormone (TSH) levels on the reproductive outcomes of in vitro fertilization patients diagnosed with endometriosis and compared to controls without endometriosis.</p><p><strong>Design: </strong>This is a retrospective cohort study on prospectively collected data.</p><p><strong>Setting: </strong>The study was conducted at tertiary care university hospital.</p><p><strong>Participants: </strong>Participants were infertile women with histopathological diagnosis of endometriosis.</p><p><strong>Methods: </strong>For 12 months (January 2018 to January 2019), women were deemed suitable and subsequently divided according to serum TSH levels above or below 2.5 mIU/L and compared to patients without endometriosis. Needed sample size was at least 41 patients for each cohort of women. Co-primary outcomes were the live birth rate (LBR), clinical pregnancy rate (CPR), and pregnancy loss rate (PLR).</p><p><strong>Results: </strong>Overall, 226 women (45 with endometriosis and 181 controls without endometriosis) were included. Diagnoses of Hashimoto thyroiditis were significantly more frequent in women with rather than without endometriosis (14/45 [31.1%] vs. 27/181 [14.9%]; p = 0.012). Similarly, in women with endometriosis, Hashimoto diagnosis rates were higher with TSH ≥2.5 mIU/L compared to TSH <2.5 mIU/L (9/15 [60%] vs.5/30 [16.6%]; p = 0.001) so were the Hashimoto diagnosis rates in control group (women without endometriosis) with TSH ≥2.5 mIU/L compared to TSH <2.5 mIU/L (17/48 [35.4%] vs. 10/133 [7.5%], respectively; p = 0.001). Effect size analysis confirmed an increased risk of Hashimoto thyroiditis in women with endometriosis and TSH ≥2.5 mIU/L compared to women with endometriosis and TSH <2.5 mIU/L (risk ratio [RR] 3.60 [95% CI 1.46-8.86]) and in women with endometriosis and TSH ≥2.5 mIU/L compared to non-endometriotic euthyroid patients (RR 7.98 [95% CI 3.86-16.48]). Dysmenorrhea risk was higher in endometriotic euthyroid women compared to euthyroid patients with no endometriosis (RR 1.87 [95% CI 1.21-2.87]). The risk was still increased in euthyroid women with endometriosis relative to dysthyroid women with no endometriosis (RR 1.97 [95% CI 1.11-3.50]). There were no significant differences between the four groups for CPR, LBR, PLR and retrieved oocytes, immature oocytes, degenerated and unfertilized oocytes, cultured blastocysts, embryos and transferred embryos.</p><p><strong>Limitations: </strong>Limitations of the study were retrospective design, limited sample size, and use of different ovarian stimulation protocol.</p><p><strong>Conclusions: </strong>Thyroid autoimmunity seems more common in women with endometriosis and TSH over 2.5 mIU/L. However, there was no significant impact on in vitro fertilization and reproductive outcomes related to the coexistence of endometriosis, Hashimoto disease, and higher T","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"413-423"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-10-12DOI: 10.1159/000534321
Francois Golfier, Michael J Seckl
Background: Today, most women with gestational trophoblastic disease (GTD) can expect to be cured, particularly if they live in middle- to high-income countries with access to GTD centres. In contrast, countries lacking organized GTD care achieve lower survival rates.
Objectives: The aim of the study was to review and consider some of the successes and areas for improvement in GTD care that have been achieved through national and international collaborations.
Methods: The authors searched PubMed and used their own knowledge of working nationally and internationally in GTD to write this review.
Conclusions: The establishment of expert centres and national systems for managing GTD is associated with the best disease outcomes. National and in particular international collaboration is most likely to result in further optimisation of management protocols and outcomes.
Outlook: It remains crucial for countries lacking GTD centres to try to establish such facilities with support from national agencies and international expert societies.
{"title":"From National to International Collaboration in Gestational Trophoblastic Disease: Hurdles and Possibilities.","authors":"Francois Golfier, Michael J Seckl","doi":"10.1159/000534321","DOIUrl":"10.1159/000534321","url":null,"abstract":"<p><strong>Background: </strong>Today, most women with gestational trophoblastic disease (GTD) can expect to be cured, particularly if they live in middle- to high-income countries with access to GTD centres. In contrast, countries lacking organized GTD care achieve lower survival rates.</p><p><strong>Objectives: </strong>The aim of the study was to review and consider some of the successes and areas for improvement in GTD care that have been achieved through national and international collaborations.</p><p><strong>Methods: </strong>The authors searched PubMed and used their own knowledge of working nationally and internationally in GTD to write this review.</p><p><strong>Conclusions: </strong>The establishment of expert centres and national systems for managing GTD is associated with the best disease outcomes. National and in particular international collaboration is most likely to result in further optimisation of management protocols and outcomes.</p><p><strong>Outlook: </strong>It remains crucial for countries lacking GTD centres to try to establish such facilities with support from national agencies and international expert societies.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"254-258"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-02-21DOI: 10.1159/000537730
Antonio Simone Laganà, Andrea Romano, Arne Vanhie, Celine Bafort, Martin Götte, Lauri A Aaltonen, Aymara Mas, Christine De Bruyn, Thierry Van den Bosch, An Coosemans, Stefano Guerriero, Sergio Haimovich, Vasilios Tanos, Marlies Bongers, Fabio Barra, Ayman Al-Hendy, Vito Chiantera, Umberto Leone Roberti Maggiore
Background: Uterine fibroids are benign monoclonal tumors originating from the smooth muscle cells of the myometrium, constituting the most prevalent pathology within the female genital tract. Uterine sarcomas, although rare, still represent a diagnostic challenge and should be managed in centers with adequate expertise in gynecological oncology.
Objectives: This article is aimed to summarize and discuss cutting-edge elements about the diagnosis and management of uterine fibroids and sarcomas.
Methods: This paper is a report of the lectures presented in an expert meeting about uterine fibroids and sarcomas held in Palermo in February 2023.
Outcome: Overall, the combination of novel molecular pathways may help combine biomarkers and expert ultrasound for the differential diagnosis of uterine fibroids and sarcomas. On the one hand, molecular and cellular maps of uterine fibroids and matched myometrium may enhance our understanding of tumor development compared to histologic analysis and whole tissue transcriptomics, and support the development of minimally invasive treatment strategies; on the other hand, ultrasound imaging allows in most of the cases a proper mapping the fibroids and to differentiate between benign and malignant lesions, which need appropriate management.
Conclusions and outlook: The choice of uterine fibroid management, including pharmacological approaches, surgical treatment, or other strategies, such as high-intensity focused ultrasound (HIFU), should be carefully considered, taking into account the characteristics of the patient and reproductive prognosis.
{"title":"Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper.","authors":"Antonio Simone Laganà, Andrea Romano, Arne Vanhie, Celine Bafort, Martin Götte, Lauri A Aaltonen, Aymara Mas, Christine De Bruyn, Thierry Van den Bosch, An Coosemans, Stefano Guerriero, Sergio Haimovich, Vasilios Tanos, Marlies Bongers, Fabio Barra, Ayman Al-Hendy, Vito Chiantera, Umberto Leone Roberti Maggiore","doi":"10.1159/000537730","DOIUrl":"10.1159/000537730","url":null,"abstract":"<p><strong>Background: </strong>Uterine fibroids are benign monoclonal tumors originating from the smooth muscle cells of the myometrium, constituting the most prevalent pathology within the female genital tract. Uterine sarcomas, although rare, still represent a diagnostic challenge and should be managed in centers with adequate expertise in gynecological oncology.</p><p><strong>Objectives: </strong>This article is aimed to summarize and discuss cutting-edge elements about the diagnosis and management of uterine fibroids and sarcomas.</p><p><strong>Methods: </strong>This paper is a report of the lectures presented in an expert meeting about uterine fibroids and sarcomas held in Palermo in February 2023.</p><p><strong>Outcome: </strong>Overall, the combination of novel molecular pathways may help combine biomarkers and expert ultrasound for the differential diagnosis of uterine fibroids and sarcomas. On the one hand, molecular and cellular maps of uterine fibroids and matched myometrium may enhance our understanding of tumor development compared to histologic analysis and whole tissue transcriptomics, and support the development of minimally invasive treatment strategies; on the other hand, ultrasound imaging allows in most of the cases a proper mapping the fibroids and to differentiate between benign and malignant lesions, which need appropriate management.</p><p><strong>Conclusions and outlook: </strong>The choice of uterine fibroid management, including pharmacological approaches, surgical treatment, or other strategies, such as high-intensity focused ultrasound (HIFU), should be carefully considered, taking into account the characteristics of the patient and reproductive prognosis.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"73-86"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-03-13DOI: 10.1159/000537692
Meiqiong Li, Jiaye Long, Miyang Yang, Yingrong Pang, Baoxiang Chen, Hong Li
Introduction: The link between cruciferous vegetables (CVs) and ovarian cancer (OC) is still uncertain. This meta-analysis is intended to investigate the association between CV consumption and the risk of OC, as well as to conduct a dose-response analysis to determine the degree of correlation between them.
Methods: We systematically searched PubMed, Web of Science, Embase, and Cochrane Library databases between database creation and October 2023. The present meta-analysis has been duly registered and assigned the registration number CRD42023470299. This study followed the PRISMA guidelines. The statistical analysis was performed using Stata 14.0 software.
Results: There were a total of 7 cohort studies and 7 case-control studies with 7,269 cases and 742,952 subjects. The combined relative risk (RR) of the highest intake of CVs was 0.90 (95% confidence intervals [CIs]: 0.84-0.96; I2 = 54.7%; p = 0.007) compared to the lowest intake of CVs. The odds ratio (OR) was 0.97 (95% CIs: 0.86-1.08; p = 0.192) for cohort studies, and the RR was 0.79 (95% CIs: 0.67-0.91; p = 0.167) for case-control studies. The intake of CVs and the risk of OC were linearly correlated. Adding 15 g of CVs to the diet each day decreased the likelihood of developing OC by almost 4% (RR = 0.963, 95% CIs: 0.905-1.025; p = 0.235).
Conclusions: Consumption of CVs may be linked to a lower risk of OC.
{"title":"The Intake of Cruciferous Vegetables and the Risk of Ovarian Cancer: A Systematic Review and Dose-Response Meta-Analysis.","authors":"Meiqiong Li, Jiaye Long, Miyang Yang, Yingrong Pang, Baoxiang Chen, Hong Li","doi":"10.1159/000537692","DOIUrl":"10.1159/000537692","url":null,"abstract":"<p><strong>Introduction: </strong>The link between cruciferous vegetables (CVs) and ovarian cancer (OC) is still uncertain. This meta-analysis is intended to investigate the association between CV consumption and the risk of OC, as well as to conduct a dose-response analysis to determine the degree of correlation between them.</p><p><strong>Methods: </strong>We systematically searched PubMed, Web of Science, Embase, and Cochrane Library databases between database creation and October 2023. The present meta-analysis has been duly registered and assigned the registration number CRD42023470299. This study followed the PRISMA guidelines. The statistical analysis was performed using Stata 14.0 software.</p><p><strong>Results: </strong>There were a total of 7 cohort studies and 7 case-control studies with 7,269 cases and 742,952 subjects. The combined relative risk (RR) of the highest intake of CVs was 0.90 (95% confidence intervals [CIs]: 0.84-0.96; I2 = 54.7%; p = 0.007) compared to the lowest intake of CVs. The odds ratio (OR) was 0.97 (95% CIs: 0.86-1.08; p = 0.192) for cohort studies, and the RR was 0.79 (95% CIs: 0.67-0.91; p = 0.167) for case-control studies. The intake of CVs and the risk of OC were linearly correlated. Adding 15 g of CVs to the diet each day decreased the likelihood of developing OC by almost 4% (RR = 0.963, 95% CIs: 0.905-1.025; p = 0.235).</p><p><strong>Conclusions: </strong>Consumption of CVs may be linked to a lower risk of OC.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"351-362"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-01-19DOI: 10.1159/000535012
Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio
Objectives: The objective of this multicenter retrospective study aimed to evaluate the association of clinical variables and the incidence of ovarian cancer in patients with BRCA 1-2 mutation carriers who underwent risk-reducing salpingo-oophorectomy (RRSO).
Design: Patients with a pathogenic mutation of BRCA 1-2 genes and with no evidence of disease are considered eligible. The exclusion criterion was the refusal to undergo the surgery. The retrospective study included all RRSO performed from May 2015 to April 2022 in the three gynecological Institutions of Southern Italy for were included in this retrospective study.
Participants/materials, setting, methods: Age, menarche age, BMI, menopause at time of RRSO, breast cancer first- and second-degree relatives, ovarian cancer first- and second-degree relatives, estroprogestin use, pregnancy normal full-term delivery, history of endometriosis, previous breast cancer and histologic type, previous abdominal/pelvic surgery, BRCA 1 or BRCA 2 status, preoperative serum CA-125 levels (IU/mL), age at time of RRSO and histological analysis were collected.
Results: 184 were recruited. One was excluded. To assess cancer risk, the outcome variable was classified into three classes: no event, cancer, and other conditions excluding cancer. 14 women presented ovarian cancer and tubal intraepithelial carcinoma (STIC) on histopathologic final report. Ovarian cancer was found in 8 patients, whereas the presence of STIC was found in 6 of them.
Limitations: The low incidence of patients diagnosed with ovarian cancer or STIC compared with the total number of patients undergoing RRSO is a potential bias.
Conclusions: Our study did not demonstrate a correlation between clinical features and the occurrence of precancerous or cancerous lesions in BRCA mutation carrier patients.
{"title":"BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study.","authors":"Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio","doi":"10.1159/000535012","DOIUrl":"10.1159/000535012","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this multicenter retrospective study aimed to evaluate the association of clinical variables and the incidence of ovarian cancer in patients with BRCA 1-2 mutation carriers who underwent risk-reducing salpingo-oophorectomy (RRSO).</p><p><strong>Design: </strong>Patients with a pathogenic mutation of BRCA 1-2 genes and with no evidence of disease are considered eligible. The exclusion criterion was the refusal to undergo the surgery. The retrospective study included all RRSO performed from May 2015 to April 2022 in the three gynecological Institutions of Southern Italy for were included in this retrospective study.</p><p><strong>Participants/materials, setting, methods: </strong>Age, menarche age, BMI, menopause at time of RRSO, breast cancer first- and second-degree relatives, ovarian cancer first- and second-degree relatives, estroprogestin use, pregnancy normal full-term delivery, history of endometriosis, previous breast cancer and histologic type, previous abdominal/pelvic surgery, BRCA 1 or BRCA 2 status, preoperative serum CA-125 levels (IU/mL), age at time of RRSO and histological analysis were collected.</p><p><strong>Results: </strong>184 were recruited. One was excluded. To assess cancer risk, the outcome variable was classified into three classes: no event, cancer, and other conditions excluding cancer. 14 women presented ovarian cancer and tubal intraepithelial carcinoma (STIC) on histopathologic final report. Ovarian cancer was found in 8 patients, whereas the presence of STIC was found in 6 of them.</p><p><strong>Limitations: </strong>The low incidence of patients diagnosed with ovarian cancer or STIC compared with the total number of patients undergoing RRSO is a potential bias.</p><p><strong>Conclusions: </strong>Our study did not demonstrate a correlation between clinical features and the occurrence of precancerous or cancerous lesions in BRCA mutation carrier patients.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"87-94"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-02-12DOI: 10.1159/000536494
Gloria Marquina, Grzegorz Szewczyk, Frederic Goffin
Background: Epithelioid Trophoblastic Tumor (ETT) and Placental Site Trophoblastic Tumor (PSTT) are two of the rarest GTNs that share certain features at diagnosis and management. Atypical Placental Site Nodule (APSN) is a relatively new entity considered as a premalignant lesion.
Objectives and methods: The aim of this review was to summarize the main characteristics of each of these entities, their diagnostic features, and their treatment's standard of care including fertility-sparing treatments.
Outcome: This study provides a thorough review of ETT, PSTT, and APSN.
Conclusions: The reader will gain an insight view of these rare tumors arising from the intermediate trophoblast.
{"title":"The Rare of the Rarest: Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Atypical Placental Site Nodule.","authors":"Gloria Marquina, Grzegorz Szewczyk, Frederic Goffin","doi":"10.1159/000536494","DOIUrl":"10.1159/000536494","url":null,"abstract":"<p><strong>Background: </strong>Epithelioid Trophoblastic Tumor (ETT) and Placental Site Trophoblastic Tumor (PSTT) are two of the rarest GTNs that share certain features at diagnosis and management. Atypical Placental Site Nodule (APSN) is a relatively new entity considered as a premalignant lesion.</p><p><strong>Objectives and methods: </strong>The aim of this review was to summarize the main characteristics of each of these entities, their diagnostic features, and their treatment's standard of care including fertility-sparing treatments.</p><p><strong>Outcome: </strong>This study provides a thorough review of ETT, PSTT, and APSN.</p><p><strong>Conclusions: </strong>The reader will gain an insight view of these rare tumors arising from the intermediate trophoblast.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"239-246"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}